Olanzapine: An updated review of its use in the management of schizophrenia

Drugs

Volumn 61, Issue 1, 2001, Pages 111-161

  Bhana, N ^a   Foster, R H ^a   Olney, R ^a   Plosker, G L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE; RISPERIDONE;

AGGRESSION; AGITATION; AGRANULOCYTOSIS; ANTICHOLINERGIC EFFECT; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAINTENANCE THERAPY; MENTAL DISEASE; QUALITY OF LIFE; RATING SCALE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; VERTIGO; WEIGHT GAIN;

EID: 0035133250     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161010-00011     Document Type: Review

References (307)

1. Olanzapine: A basic science update
2. Olanzapine: A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses
3. Olanzapine: A pharmacoeconomic review of its use in schizophrenia
4. 2 receptors
5. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
6. Risperidone; a review of its use in the management of the behavioural and psychological symptoms of dementia
7. Psychopharmacology of olanzapine. A review
8. In vitro and in vivo biochemistry of olanzapine: A novel, atypical antipsychotic drug
9. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors
10. Pre-clinical pharmacology of atypical antipsychotic drugs: A selective review
11. Relationship between the individuals differences in the plasma antiserotonine activity to anti-dopamine activity ratio and manifestation of drug-induced extrapyramidal symptoms in serotonin-dopamine antagonist
12. Receptor pharmacology of neuroleptics: Relation to clinical effects
13. 1-adrenergic receptors in vitro
14. 123I IBZM single photon emission tomography (SPET) study
15. Implications of brain imaging for the management of schizophrenia
16. Visualisation of dopamine-2 receptor occupancy in psychotic patients treated with olanzapine, risperidone, clozapine and haloperidol
17. 2 receptor occupancy in olanzapine-treated patients
18. 2 receptor occupancy of olanzapine in schizophrenia: A PET investigation
19. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
20. Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors
21. Effects of olanzapine on regional C-Fos expression in rat forebrain
22. Mechanisms of action of atypical antipsychotic drugs: A critical analysis
23. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors
24. The behavioral pharmacology of olanzapine, a novel atypical antipsychotic agent
25. 2-like' agonist RU 24213
26. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability
27. Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test
28. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice
29. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine
30. The novel atypical antipsychotic olanzapine, but not the CCK-B antagonist LY288513, blocks apomorphine-induced disruption of prepulse inhibition
31. Effect of olanzapine on behavioural changes induced by FG 7142 and dizocilpine on active avoidance and plus maze tasks
32. The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: Effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine
33. Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons
34. Olanzapine moderately increases conflict responding but does not produce a benzodiazepine-like cue in rat
35. Effects of typical and atypical antipsychotic drugs on freezing behavior induced by conditioned fear
36. Differential effect of antipsychotics on place navigation of rats in the Morris water maze: A comparative study between novel and reference antipsychotics
37. Behavioral pharmacology of olanzapine: A novel antipsychotic drug
38. Do novel antipsychotics have similar pharmacologial characteristics? A review of the evidence
39. Olanzapine: Pharmacokinetic and pharmacodynamic profile
40. Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency
41. Effects of olanzapine on sleep EEG in schizophrenic patients
42. Olanzapine: Interaction study with imipramine
43. Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor
44. Change in basal ganglia volume over 2 years in patients with schizophrenia: Typical versus atypical neuroleptics
45. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum
46. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
47. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
48. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations
49. Pharmacokinetics of olanzapine in elderly and young [abstract no. PPDM 8126]
50. Disposition and biotransformation of the antipsychotic agent olanzapine in humans
51. Olanzapine serum concentrations in psychiatric patients given standard doses: The influence of comedication
52. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients
53. Plasma level monitoring of olanzapine in patients with schizophrenia: Determination by high-performance liquid chromatography with electrochemical detection
54. Olanzapine transfer by human placenta
55. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine
56. Combined population pharmacokinetic analysis of olanzapine in healthy volunteers
57. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial
58. Monitoring of serum olanzapine during antipsychotic treatment
59. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C19, CYP2C10, CYP2D6, and CYP3A
60. Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men
61. Interaction between olanzapine and lithium in healthy male volunteers
62. Fluvoxamine is a potent inhibitor of cytochrome P4501A2
63. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: Potent inhibition by fluvoxamine
64. Pharmacokinetic (PK) and pharmacodynamic (PD) interactions between fluvoxamine and olanzapine
65. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration
66. A pharmacokinetic interaction between carbamazepine and olanzapine: Observations on possible mechanism
67. Five-factor model of schizophrenia: Initial validation
68. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
69. Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial
70. The Brief Psychiatric Rating Scale
71. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
72. Scale for the assessment of negative symptoms (SANS)
73. Rating scales in schizophrenia: A review of their usefulness for assessing atypical antipsychotics
74. Olanzapine optimal dose: Results of an open-label multicenter study in schizophrenic patients
75. Olanzapine vs fluphenazine - 6 weeks treatment of acute schizophrenia
76. Olanzapine compared to chlorpromazine in acute schizophrenia
77. A comparison of newer vs traditional antipsychotics and placebo using meta-analysis techniques
78. Risperidone: A review of its pharmacology and therapeutic potential in the treatment of schizophrenia
79. A comparison of clinical outcome of four atypical neuroleptics in the treatment of schizophrenia
80. Differential effects of antipsychotic drugs on clinical symptoms and cognitive functions in the treatment of schizophrenia
81. A retrospective, naturalistic review comparing clinical outcomes of in-hospital treatment with risperidone and olanzapine
82. New neuroleptics: An eight-year naturalistic study
83. Direct and indirect treatment comparisons of second-generation antipsychotic drugs
84. Comparisons of costs and effects of risperidone treatment versus olanzapine treatment in daily practice
85. Efficacy of risperidone vs olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder
86. Olanzapine versus risperidone in the treatment of schizophrenia and related psychotic disorders
87. Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS) single-center report from an international study series
88. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia
89. Doses of olanzapine, risperidone and haloperidol used in clinical practice: Results of a prospective pharmacoepidemiological study
90. The safety of olanzapine compared with other antipsychotic drugs: Results of an observational prospective study in patients with schizophrenia (EFESO study)
91. Comments on article by Tran and associates, 'Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders'
92. Comments on article by Tran and colleagues, 'Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders'
93. Comments on 'Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders' by Tran and Associates
94. Use of risperidone and olanzapine in outpatient clinics at six veterans affairs hospitals
95. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials
96. Risperidone and olanzapine: Optimal dosing for efficacy and tolerability in patients with schizophrenia
97. Risperidone: A pharmacoeconomic review of its use in schizophrenia
98. Comments on article by Tran and associates, double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and psychotic disorders. Reply
99. Double-blind comparison of olanzapine versus risperdone in the treatment of schizophrenia and other psychotic disorders. Reply
100. Comments on article by Tran and colleagues, 'double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders.' Reply [letters]
101. Schizophrenia
102. Relapse prevention with olanzapine
103. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses
104. Olanzapine versus haloperidol treatment in first-episode psychosis
105. Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine
106. Change in positive symptoms with olanzapine compared to other antipsychotic agents
107. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine
108. Olanzapine versus amisulpride and placebo in the treatment of negative symptoms and deficit states of chronic schizophrenia
109. The effects of neurocognitive remediation on executive processing in patients with schizophrenia
110. Interventions for neurocognitive deficits: Editor's introduction
111. Effects of olanzapine on neurocognition in schizophrenia
112. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
113. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol
114. Risperidone, olanzapine, phenotiazines and neuropsychological tests in schizophrenia
115. Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder
116. The role of typical and atypical antipsychotic medications in the management of agitation and aggression
117. A double-blind study of intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients
118. Psychoses in the elderly: A spectrum of disorders
119. Olanzapine reduces psychosis and behavioral disturbances associated with Alzheimer's disease
120. Experience with the atypical antipsychotics - Risperidone and olanzapine in the elderly
121. Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol
122. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders
123. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia
124. The course of depressive symptoms in predicting relapse in schizophrenia: A doubleblind, randomized comparison of olanzapine and risperidone
125. Olanzapine vs fluphenazine: Treatment of acute schizophrenic symptomatology and anxiety
126. Predictive value of early anti-anxiety effect on the acute-antipsychotic outcome; a comparison of fluphenazine and olanzapine
127. Sex differences in response to treatment with olanzapine: A preliminary analysis
128. Clinical experience with olanzapine in patients of African, Asian, and Hispanic descent
129. Efficacy and safety study comparing olanzapine versus haloperidol in the treatment of Chinese patients with schizophrenia in Taiwan and Hong Kong
130. Olanzapine in a middle Asian patient population with acute schizophrenia
131. Pharmacologic treatment of first-episode schizophrenia: Early intervention is key to outcome
132. Olanzapine vs Haloperidol on treatment of first-episode psychois: HGDH study group [poster]. Schizophrenia: Across the life cycle
133. Evaluation of treatment-resistant schizophrenia
134. Role of newer atypical antipsychotics in the management of treatment-resistant schizophrenia
135. Treatment of special populations with the atypical antipsychotics
136. Clozapine: A review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents
137. Clozapine for the treatment-resistant schizophrenic
138. Double-Blind comparion of olanzapine versus clozapine in shizophrenic patients clinically eligible for treatment with clozapine
139. Olanzapine versus clozapine in patients non-responsive or intolerant to standard acceptable treatment of schizophrenia
140. Olanzapine versus clozapine in patients non-responsive or intolerant to standard acceptable treatment of schizophrenia
141. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia
142. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia
143. An open trial of olanzapine in poorly responsive psychosis
144. Olanzapine in patients non responsive or intolerant to risperidone
145. Treatment failure with risperidone: Can olanzapine be an alternative therapy?
146. The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine
147. Olanzapine in treatment-refractory schizophrenia: Results of an open-label study
148. An open trial of olanzapine in patients with treatment-refractory psychoses
149. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response
150. Olanzapine for patients with treatment-resistant schizophrenia: A naturalistic case-series outcome study
151. High-dose olanzapine therapy in schizophrenia
152. Schizophrenia and schizoaffective disorder treated with high doses of olanzapine
153. Olanzapine in schizophrenia-refractory atypicals
154. Use of high-dose olanzapine in refractory psychosis
155. High-dose olanzapine for treatment-refractory schizophrenia
156. The use of olanzapine in non-compliant or treatment-resistant clozapine populations in hospital
157. Olanzapine as medication of first choice in therapy resistant schizophrenia?
158. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse
159. Management of treatment-resistant schizophrenia with olanzapine
160. Olanzapine for treatment-refractory psychosis in patients responsive to, but intolerant of, clozapine
161. Typical and atypical antipsychotics in adolescent schizophrenia: Efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms
162. Olanzapine in the treatment of early onset schizophrenia in children and adolescents
163. Use of atypical neuroleptics in child and adolescent psychiatry
164. Childhood-onset schizophrenia: An open-label study of olanzapine in adolescents
165. Olanzapine treatment of psychotic adolescents - Change of body weight and adverse event profile
166. High-dose olanzapine in an adolescent
167. Psychosis in late life: Spotting new-onset disorders in your elderly patients
168. Management of psychosis and agitation in elderly patients: A primary care perspective
169. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients
170. Olanzapine treatment of psychotic and behavioural symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial
171. Efficacy and tolerabitity of olanzapine in elderly patients with psychotic disorders: A prospective study
172. Olanzapine therapy in elderly patients with schizophrenia
173. Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders
174. Tolerability and efficacy of atypical antipsychotics in male geriatric inpatients
175. Retrospective one-year review of the outcomes of atypical antipsychotic use at Central Texan Veterans Health Care System
176. Comparison of atypical agents and haloperidol in nursing home patients
177. Safety of olanzapine
178. Novel antipsychotic medications in the treatment of children and adolescents
179. Olanzapine in adolescents with a psychotic disorder
180. Weight gain as side-effect of olanzapine and risperidone in adolescent patients with schizophrenia
181. New atypical antipsychotics: Experience and utility in the elderly
182. Conventional vs. newer antipsychotics in elderly patients
183. Cardiac safety profile of olanzapine based on preclinical and clinical ECG data
184. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia
185. Two cases of olanzapine-induced reversible neutropenia
186. Olanzapine-induced agranulocytosis
187. Olanzapine-induced neutropenia after clozapine-induced neutropenia
188. Olanzapine after clozapine: The rare case of prolongation of granulocytopaenia
189. Prolongation of clozapine-induced granulocytopenia associated with olanzapine
190. Olanzapine treatment after clozapine induced agranulocytosis
191. Olanzapine treatment in patients with typical and atypical neuroleptic-associated agranulocytosis
192. Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients
193. New-onset diabetes and ketoacidosis with atypical antipsychotics
194. New-onset diabetes mellitus associated with the initiation of quetiapine treatment
195. Diabetic ketoacidosis associated with risperidone treatment
196. Hyperglycemia and olanzapine
197. Hyperglycemia associated with olanzapine
198. Novel antipsychotics and new onset diabetes
199. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment
200. Diabetic ketoacidosis with olanzapine treatment
201. Olanzapine-induced ketoacidosis with diabetes mellitus
202. Weight gain associated with antipsychotic drugs
203. Novel antipsychotics: Comparison of weight gain liabilities
204. Antipsychotic-induced weight gain: A comprehensive research synthesis
205. Effect of long-term olanzapine treatment on weight change in schizophrenia
206. Weight and metabolic changes with clozapine and olanzapine
207. Factors associated with weight gain during olanzapine treatment
208. Olanzapine: Weight gain and therapeutic efficacy
209. Olanzapine-induced elevation of plasma triglyceride levels
210. Weight gain in pediatric patients on typical and atypical antipsychotics
211. The relationship of pharmacology to side effects
212. Seizure associated with olanzapine
213. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia
214. Safety and effectiveness of olanzapine versus typical antipsychotic drugs in the treatment of inpatients with schizophrenia (EUROPA study)
215. Olanzapine for the treatment of tardive dyskinesia
216. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
217. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol
218. Effect of chronic olanzapine treatment on the course of presumptive tardive dyskinesia
219. Marked reduction of tardive dyskinesia with olanzapine
220. Reduction of tardive dystonia with olanzapine
221. Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject
222. Olanzapine in the treatment of tardive dyskinesia: A report of two cases
223. Improvement of tardive dyskinesia following treatment with olanzapine
224. Neuroleptic malignant syndrome associated with olanzapine therapy
225. Recurrence of neuroleplic malignant syndrome with olanzapine treatment
226. Atypical neuroleptic malignant syndrome?
227. Neuroleptic malignant syndrome associated with olanzapine
228. Olanzapine-induced neuroleptic malignant syndrome with mental retardation
229. Case report: Possible neuroleptic malignant syndrome associated with olanzapine
230. Olanzapine induced neuroleptic malignant syndrome
231. Neuroleptic malignant syndrome associated with olanzapine
232. Marked elevation of serum creatine kinase associated with olanzapine therapy
233. Acute olanzapine overdose
234. Olanzapine overdose with serum concentrations
235. Olanzapine overdose
236. Olanzapine overdose
237. Olanzapine-induced manic-like syndrome
238. Aggression, agitation, and mania with olanzapine
239. Mania-like syndrome in a patient with chronic schizophrenia during olanzapine treatment
240. Olanzapine-induced mania
241. Hypomania-like syndrome induced by olanzapine
242. Olanzapine-induced obsessive-compulsive disorder
243. Worsening of obsessive-compulsive symptoms following treatment with olanzapine
244. Possible induction of mania and hypomania by olanzapine or risperidone: A critical review of reported cases
245. Formulary decisions and health economics
246. Are patients with schizophrenia denied the best treatment?
247. Pharmacocconomics of clozapine, risperidone and olanzapine: A review of the literature
248. Treatment of schizophrenia: Let's talk dollars and sense
249. Measuring the effect of treatment on quality of life in patients with schizophrenia: Focus on utility-based measures
250. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia
251. Measuring quality of life in patients with schizophrenia
252. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: Results from a randomised clinical trial
253. An economic comparison of olanzapine versus haloperidol in the treatment of schizophrenia in France
254. Olanzapine versus risperidone: A prospective comparison of clinical and economic outcomes in schizophrenia
255. Mixed-model imputation of cost data for early discontinuers from a randomized clinical trial
256. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia
257. Cost-effectiveness of atypical antipsychotics in chronic schizophrenia
258. A cost-effectiveness clinical decision analysis model for schizophrenia
259. Cost analysis of the treatment of schizophrenia in the UK: A simulation model comparing olanzapine, risperidone and haloperidol
260. Cost analysis of the treatment of schizophrenia in the UK: A comparison of olanzapine and haloperidol
261. Cost effectiveness analysis of olanzapine compared with haloperidol in the treatment of schizophrenia in Spain
262. Cost analysis of schizophrenia treatment in Germany: A comparison of olanzapine, risperidone, and haloperidol using a clinical decision model
263. Pharmacoeconomic evaluation of the treatment of schizophrenia in Germany: A comparison of olanzapine and haloperidol
264. Cost effectiveness of olanzapine in comparison to risperidone and haloperidol
265. A cost-effectiveness clinical decison analysis for schizophrenia: Results from Sweden
266. A cost-effectiveness clincial decision analysis for schizophrenia: Results from Sweden
267. Olanzapine in practice
268. The economic value of atypical antipsychotics: A comparison of risperidone and olanzapine revisited
269. RODOS: An international naturalistic study: Final results
270. Comparison of cost, dosage and clinical preference for risperidone and olanzapine
271. A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium
272. Risperidone and olanzapine drug use in a Bavarian district hospital
273. A comparative analysis of risperidone and olanzapine dosing patterns in the South Carolina Medicaid Program
274. Drug and resource use evaluation of risperidone and olanzapine in inpatients with outpatient follow-up
275. The cost of inpatient treatment of schizophrenia: A study of two leading atypical antipsychotics
276. Risperidone versus olanzapine: Discharge rates and economic considerations
277. Higher cost of olanzapine compared to risperidone in acute psychotic relapse
278. Use of atypical antipsychotics in a Veterans Affairs hospital
279. Risperidone Olanzapine Drug Outcomes Study in Schizophrenia (RODOS) - First results of the German data
280. Atypical neuroleptics in a German hospital
281. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine
282. Costs-benefits of resource utilization in the Quebec welfare recipients population using two atypical drug products
283. Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study
284. Cost impact of using olanzapine at a Veterans Affairs Medical Center
285. Economic evaluation of risperidone in an outpatient population
286. Efficacy and fiscal impact of atypical antipsychotics in county-wide outpatient managed care services
287. Cost-effectiveness of risperidone versus olanzapine in schizophrenia: A computer database evaluation
288. Reliability, validity, and application of the medical outcomes study 36-item shortform health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol
289. Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial
290. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial
291. Subjective experience olanzapine, other antipsychotics
292. Antipsychotic treatment and changes in health related quality of life in patients with schizophrenia using EQ-5D
293. Functional outcomes in schizophrenia: A European comparison of olanzapine and haloperidol
294. Olanzapine
295. Dosing the antipsychotic medication olanzapine
296. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment
297. Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?
298. Facilitating compliance with antipsychotic medication
299. Practice guideline for the treatment of patients with schizophrenia
300. Improvement of psychosocial treatment with atypical antipsychotics
301. Treatment of schizophrenia 1999
302. Tolerability of atypical antipsychotics